Clinical effects of simvastatin in chronic hepatitis C patients receiving sofosbuvir/daclatasvir combination. A randomized, placebo-controlled, double-blinded study

AIM OF THE STUDY: Chronic hepatitis C (CHC) affects more than 71 million people worldwide. Many therapies containing different direct-acting antivirals (DAAs) are now used. However, lipid profile is considered an important outcome with DAAs. So, this study aimed to assess clinical effects of statins...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Hossam Z, Sabri, Nagwa A, Zaki, Hossam M, Shaheen, Sara M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380473/
https://www.ncbi.nlm.nih.gov/pubmed/32728626
http://dx.doi.org/10.5114/ceh.2020.95566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380473/
https://www.ncbi.nlm.nih.gov/pubmed/32728626
http://dx.doi.org/10.5114/ceh.2020.95566

Ejemplares similares